A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)

Trial ID or NCT#

NCT02511405

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.

Official Title

A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. First or second progression of Glioblastoma; 2. Measurable disease by RANO criteria at progression; 3. Patients ≥18 years of age; 4. Patient may have been operated for recurrence. If operated: residual and measurable disease after surgery is required; 5. Surgery completed at least 28 days before randomization; 6. An interval of at least 12 weeks between prior radiotherapy or at least 23 days from prior chemotherapy, 42 days from nitrosoureas and enrollment in this study; 7. Adequate performance, i.e."Karnofsky Performance Score" of at least 70%; 8. Adequate renal, liver, and bone marrow function according to the following criteria: - Absolute neutrophil count ≥1500 cells/ml, - Platelets ≥ 100,000 cells/ml, - Total bilirubin within upper limit of normal (ULN), - Aspartate aminotransferase (AST) ≤ 2.0 X ULN, - Serum creatinine level ≤ ULN or creatinine clearance ≥ 50 ml/min for patients with creatinine levels above normal limits (creatinine clearance calculated by the Cockcroft-Gault formula, see Appendix II), - PT, PTT (in seconds) not to be prolonged beyond >20% of the upper limits of normal.
Exclusion Criteria:
  1. 1. Prior anti-angiogenic therapy including VEGF sequestering agents (i.e. bevacizumab, aflibercept, etc.) or VEGFR inhibitors (cedirinib, pazopanib, sunitinib, sorafenib, etc.); 2. Prior stereotactic radiotherapy; 3. Pregnant or breastfeeding patients; 4. Concomitant medication that may interfere with study results; e.g. immunosuppressive agents other than corticosteroids; 5. Active infection; 6. Evidence of significant CNS haemorrhage i.e. CTCAE grade 2 or above; 7. Expected to have surgery during study period; 8. Patients with active vascular disease, either myocardial or peripheral (i.e. acute coronary syndrome, cerebral stroke, transient ischemic attack or arterial thrombosis or symptomatic peripheral vascular disease within the past 3 months); 9. Patients with known proliferative and/or vascular retinopathy; 10. Patients with known liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune); 11. Patients with known active second malignancy other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast. Patients are not considered to have a currently active malignancy if they have completed anticancer therapy and have been disease free for greater than 2 years prior to screening; 12. Patients testing positive to one of the following viruses: HIV, HBV and HCV within the last 6 months; 13. Patients that have undergone major surgery within the last 4 weeks before enrollment; 14. Patients who have received treatment with any other investigational agent within 4 weeks before enrollment.

Investigator(s)

Seema Nagpal, MD
Seema Nagpal, MD
Neuro-oncologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Reena Thomas, MD PhD
Reena Thomas, MD PhD
Neuro-oncologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061